Biotechnology Securities Law In Ukraine.

1. Introduction

Biotechnology Securities Law in Ukraine refers to the legal framework governing the issuance, offering, trading, ownership, disclosure and regulation of securities issued by biotechnology companies, pharmaceutical enterprises, genetic-research organisations, medical technology businesses and life-sciences investment companies.

Biotechnology businesses often require substantial long-term capital for activities such as:

Development of vaccines, medicines and biological products.

Genetic engineering and gene-therapy research.

Clinical trials and pharmaceutical innovation.

Development of artificial organs and regenerative medicine.

Biotechnology patents and intellectual property commercialisation.

Construction of laboratories and pharmaceutical manufacturing facilities.

Ukrainian law does not establish an entirely separate securities regime for biotechnology companies. Instead, biotechnology businesses are generally subject to Ukraine's ordinary securities, corporate, investment, pharmaceutical, intellectual-property and data-protection laws.

The central legal challenge is ensuring that biotechnology investment remains transparent and commercially lawful while protecting investors, patients, research participants and public interests.

2. Constitutional and legislative framework

The Ukrainian legal framework consists of the following principal laws.

LegislationRelevance to biotechnology securities
Constitution of Ukraine, 1996Property rights, economic freedom and judicial protection
Law No. 3480-IV on Securities and Stock Market, 2006, as amendedHistorical securities legislation; read together with the newer capital-markets framework
Law No. 738-IX on Capital Markets and Organised Commodity Markets, 2020Issuance, circulation, trading and disclosure of financial instruments
Law No. 2465-IX on Joint-Stock Companies, 2022Shareholder rights, corporate governance and share issuance
Law No. 5178-VI on the Depositary System of Ukraine, 2012Recording ownership and rights in securities
Law No. 448/96-VR on State Regulation of the Securities Market, 1996Regulatory supervision and enforcement
Law No. 2275-VIII on Limited and Additional Liability Companies, 2018Corporate structure and investment in biotechnology businesses

Important legislative distinction: The 2020 capital-markets reform introduced the principal modern framework. The older Law on Securities and Stock Market should not be treated as the only governing legislation. The current version of the legislation must be checked when analysing a transaction.

zakon.rada.gov.ua+3

 

3. Regulatory authorities

The main regulatory authority is the National Securities and Stock Market Commission (NSSMC).

Its responsibilities include:

Registration and supervision of securities issues.

Monitoring public securities offerings.

Supervision of professional capital-market participants.

Investor protection.

Enforcement of disclosure obligations.

Monitoring securities-market misconduct.

Maintaining registers of securities issues and market participants.

The Commission's official registers include securities issues, investment funds and licensed market participants.

nssmc.gov.ua+1

 

Other relevant authorities include:

National Bank of Ukraine (NBU): financial stability, banking and relevant foreign-exchange matters.

Antimonopoly Committee of Ukraine (AMCU): competition and merger control.

Ministry of Health of Ukraine: pharmaceutical and medical-product regulation.

State Expert Centre of the Ministry of Health: relevant medicinal-product regulatory and expert functions.

The securities regulator does not replace pharmaceutical regulators. A biotechnology company may comply with securities law while still violating medicinal-product or clinical-trial requirements.

4. Types of securities available to biotechnology companies

Ukrainian biotechnology companies may use several financing instruments.

A. Ordinary shares

Shares are used to raise equity capital and provide investors with ownership rights in a joint-stock company.

For example, a Ukrainian genetic-engineering company may issue shares to finance:

Gene-editing research.

Laboratory infrastructure.

Clinical research.

Commercial production of biological medicines.

Shareholders may receive dividends, participate in corporate governance and exercise other rights established by law and the company's constitutional documents.

B. Corporate bonds

Corporate bonds represent debt obligations of the issuing company.

A pharmaceutical manufacturer may issue bonds to finance a new vaccine-production facility.

The issuer must comply with the applicable issuance, disclosure and repayment requirements.

Unlike shareholders, bondholders generally have creditor rights rather than ownership rights.

C. Investment fund securities

Investment funds can provide indirect exposure to biotechnology businesses.

An investment fund may invest in:

Pharmaceutical manufacturers.

Medical technology enterprises.

Biotechnology research companies.

Companies commercialising genetic technologies.

The investment fund structure must comply with Ukrainian collective investment legislation and applicable regulatory requirements.

D. Derivative securities

Derivatives may be used for investment, hedging and other financial purposes.

For example, a biotechnology investor may use an appropriate financial instrument to manage exposure to the value of a portfolio of pharmaceutical shares.

Such arrangements must comply with the applicable capital-market rules.

The NSSMC identifies equity securities, debt securities and derivative securities within the Ukrainian securities framework.

nssmc.gov.ua+1

 

5. Issuance and registration of biotechnology securities

A biotechnology company wishing to raise capital through a securities issue must follow the relevant corporate and securities procedures.

The process generally involves:

Step 1: Corporate authorisation

The company must obtain the necessary decision from its competent corporate body to issue securities.

Step 2: Determine the securities structure

The company determines the type, quantity, nominal value and other terms of the proposed issue.

Step 3: Prepare documentation

Depending on the offering, documents may include:

Corporate resolutions.

Financial statements.

Information about the issuer.

Details of the securities.

Information about existing shareholders.

Risk disclosures.

A prospectus where required.

Step 4: Regulatory registration

The company follows the applicable NSSMC registration and approval requirements.

Step 5: Placement

Securities are placed with investors in accordance with the approved terms and applicable exemptions.

Step 6: Depositary registration

Ownership and rights in securities are recorded through the Ukrainian depositary system.

The NSSMC's Resolution No. 1308 of 22 November 2023 established an updated procedure for share issuance, registration and cancellation of registration.

nssmc.gov.ua+1

 

6. Prospectus disclosure and biotechnology investment risks

Prospectus disclosure is particularly important in biotechnology because scientific and commercial uncertainty can significantly affect the value of securities.

A biotechnology issuer must not present unverified scientific claims as established commercial achievements.

Relevant disclosures may include:

A. Scientific risks

Failure of gene-editing experiments.

Inadequate reproducibility of research.

Failure to demonstrate clinical efficacy.

Unexpected adverse effects.

B. Regulatory risks

Rejection or delay of medicinal-product approval.

Suspension of clinical trials.

Manufacturing compliance problems.

Changes in pharmaceutical regulation.

C. Intellectual-property risks

Patent invalidity.

Patent infringement litigation.

Disputes over ownership of research inventions.

Licensing restrictions.

D. Financial risks

High research expenditure.

Insufficient cash reserves.

Dependence on government grants.

Failure to attract further investment.

E. Operational risks

Laboratory contamination.

Manufacturing interruptions.

Loss of specialist researchers.

Supply-chain disruption.

For example, if a company claims that its experimental gene therapy has completed successful clinical trials when the relevant evidence is incomplete, the statement may create securities-law liability.

A prospectus should distinguish between laboratory findings, preclinical results, clinical-trial outcomes and actual regulatory approval.

The general disclosure framework is supported by the Ukrainian capital-markets regime and the NSSMC's issuer-disclosure requirements.

nssmc.gov.ua+2

 

7. Shareholder rights and biotechnology corporate governance

The Law on Joint-Stock Companies, No. 2465-IX, is particularly relevant to biotechnology enterprises organised as joint-stock companies.

Shareholders may exercise rights concerning:

Participation in general meetings.

Voting on corporate decisions.

Receipt of dividends where declared.

Access to information as prescribed by law.

Protection against unlawful dilution.

Challenging unlawful corporate decisions.

Exercising applicable preferential rights.

Biotechnology companies have additional governance challenges because founders, scientific researchers, patent owners and financial investors may have conflicting interests.

For example, a founder may wish to retain control over gene-therapy research, while an institutional investor may demand greater financial supervision.

A shareholders' agreement can address matters such as:

Board representation.

Reserved corporate decisions.

Future capital increases.

Transfer restrictions.

Intellectual-property licensing.

Exit arrangements.

Confidentiality and research-commercialisation obligations.

However, a shareholders' agreement cannot override mandatory Ukrainian corporate and securities legislation.

8. Case laws and judicial interpretation

An important point is that Ukrainian reported securities decisions generally concern ordinary companies, shareholders, pharmaceutical manufacturers and securities transactions. There is no established separate body of reported Supreme Court jurisprudence specifically dealing with biotechnology securities.

Nevertheless, several Ukrainian judicial decisions provide important principles that can be applied to biotechnology-sector securities disputes.

Case 1: Supreme Court decision concerning securities ownership and share registration (19 April 2023)

SUPREME COURT OF UKRAINE – COMMERCIAL CASSATION COURT

Facts:

A company challenged the NSSMC's decision to register a share issue by another joint-stock company. It requested cancellation of the share-issue registration and related regulatory certificates.

Legal issue:

Whether the registration of a securities issue could be challenged without adequate documentary proof of the alleged irregularities and competing shareholder ownership.

Judicial principle:

The Supreme Court explained that an extract from the depositor's securities account is documentary evidence of the existence of securities rights at the relevant time.

The Court also examined the Commission's supervisory responsibilities and the absence of sufficient evidence that it had failed to perform those responsibilities.

Relevance to biotechnology:

Suppose a biotechnology company issues additional shares to finance genetic research. An existing shareholder alleges that the new issue unlawfully diluted their ownership.

The shareholder must produce appropriate evidence of their securities rights and establish the relevant legal violation.

Legal significance: Securities ownership must be established through the legally recognised depositary records, rather than unsupported assertions.

КГС ВС

Case 2: Darnitsa Pharmaceutical Company v. Dispute Concerning Borshchahivskiy Chemical-Pharmaceutical Plant Shares (29 October 2020)

SUPREME COURT OF UKRAINE – PHARMACEUTICAL SHARE OWNERSHIP DISPUTE

Facts:

Pharmaceutical company Darnitsa acquired approximately 29.95% of the shares in the Research and Production Centre Borshchahivskiy Chemical-Pharmaceutical Plant through an exchange auction in 2015.

The transaction was challenged in litigation involving the acquisition of the shares.

Legal issue:

Whether the acquisition of the pharmaceutical company's shares through the privatisation and exchange-auction process was lawful.

Judicial outcome:

On 29 October 2020, the Supreme Court upheld the legality of the acquisition and restored the first-instance court's decision in Darnitsa's favour.

The dispute also involved earlier litigation concerning the rights of minority shareholders.

Relevance to biotechnology:

The judgment is relevant to pharmaceutical and biotechnology companies because it illustrates the importance of:

Lawful acquisition of corporate securities.

Protection of ownership rights.

Compliance with share-transfer procedures.

Legality of corporate-control transactions.

Protection of minority shareholder interests.

It is particularly relevant where an investor acquires a substantial interest in a biotechnology or pharmaceutical enterprise.

Фармацевтична компанія "Дарниця"+1

Case 3: Supreme Court Review of Securities-Circulation Disputes (24 June 2022)

COMMERCIAL CASSATION COURT – SECURITIES JURISPRUDENCE REVIEW

Background:

The Supreme Court published a review of the Commercial Cassation Court's decisions concerning securities disputes during 2021.

The review addressed:

Jurisdiction over securities disputes.

Appropriate remedies for securities-rights violations.

Interim judicial protection.

Securities purchase and sale disputes.

Protection of rights arising from shares.

Promissory-note disputes.

Bond-related disputes.

Legal significance:

The review provides a useful framework for determining the appropriate judicial remedy when securities rights are violated.

Biotechnology application:

If an investor purchases shares in a biotechnology company and the company unlawfully refuses to recognise the investor's rights, the investor may need to seek an appropriate corporate or securities-law remedy.

The correct remedy depends on the nature of the violation and the evidence.

supreme.court.gov.ua+1

Case 4: Chemex LTD and the share-registration dispute involving Kremenchuk Technical Carbon Plant

COMMERCIAL CASSATION COURT – SHARE-ISSUE REGISTRATION

Facts and legal issue:

The litigation concerned objections to the registration of a share issue by the Kremenchuk Technical Carbon Plant. The objections included allegations of inaccurate or incomplete documentation and irregularities concerning the shareholder information.

Judicial principle:

The court's analysis emphasised that allegations of inaccurate documentation must be supported by evidence. The mere assertion that the regulator should have refused registration is insufficient.

The case material also discusses the legal grounds on which the NSSMC may refuse registration of a share issue.

Biotechnology application:

A biotechnology company applying for registration of a share issue must ensure that its corporate documents, shareholder information and securities-issue documentation are accurate and complete.

A regulator's registration decision should be challenged on properly established legal grounds.

supreme.court.gov.ua

Case-law qualification: The above cases are relevant by analogy. They should not be described as direct judicial decisions on gene-editing, clinical-trial financing or biotechnology-specific securities instruments.

9. Securities fraud and misleading biotechnology investment claims

Biotechnology companies frequently attract investment based on scientific developments that have not yet achieved commercial success.

This creates the possibility of securities fraud.

Examples include:

Claiming that a drug has received regulatory approval when it has not.

Fabricating clinical-trial results.

Misrepresenting the commercial value of a genetic-engineering patent.

Concealing regulatory investigations.

Falsifying research partnerships.

Providing misleading financial statements.

Concealing material manufacturing failures.

Ukrainian securities law requires issuers to comply with applicable disclosure obligations.

Depending on the circumstances, misconduct may result in:

Regulatory sanctions.

Civil liability.

Compensation claims.

Corporate disputes.

Criminal investigation where the elements of a criminal offence are established.

A particularly important issue is the distinction between a failed scientific experiment and intentional securities fraud.

A failed experiment does not automatically establish fraud. Liability depends on whether the company breached an applicable legal obligation, misrepresented material information or engaged in other unlawful conduct.

10. Biotechnology intellectual property and securities valuation

Intellectual property is a significant component of biotechnology company valuation.

Relevant assets include:

Patents for biological inventions.

Pharmaceutical manufacturing processes.

Gene-editing technologies.

Proprietary laboratory methods.

Research databases.

Licensed biological technologies.

Software used in medical research.

A biotechnology company may raise investment by issuing shares on the basis of its intellectual-property portfolio.

However, the company must establish that it has legally enforceable rights to the assets being presented to investors.

Important legal issues include:

Patent ownership: Whether the biotechnology company owns the relevant invention or merely holds a licence.

Employee inventions: Whether researchers have validly transferred or assigned the relevant rights.

Research collaborations: Whether agreements with universities or research institutions permit commercial exploitation.

Patent disputes: Whether competing patent claims could affect the company's ability to commercialise its technology.

Valuation transparency: Whether the claimed intellectual-property value is supported by credible evidence.

A company should not represent an unapproved experimental technology as an established commercially successful product.

11. Foreign investment and cross-border securities transactions

Ukraine's biotechnology industry may attract foreign investment from pharmaceutical companies, venture-capital funds, institutional investors and international research organisations.

Cross-border investment creates several legal challenges.

A. Foreign investor participation

Foreign investors may acquire interests in Ukrainian companies subject to applicable corporate, securities, investment and national-security restrictions.

B. Foreign securities offerings

A Ukrainian biotechnology company seeking to raise capital outside Ukraine must comply with the relevant foreign jurisdiction's securities laws as well as applicable Ukrainian requirements.

C. Foreign exchange compliance

Cross-border subscription payments, dividends and investment proceeds must comply with Ukrainian currency legislation and applicable National Bank restrictions.

D. Sanctions compliance

Investors and issuers must consider Ukrainian sanctions legislation, beneficial ownership, restricted counterparties and applicable international sanctions.

E. Intellectual-property transfers

Foreign investment agreements should clearly distinguish ownership of biotechnology patents, licensing rights, research results and commercialisation rights.

12. Securities regulation during martial law

Ukraine's martial-law environment creates additional challenges for biotechnology investment.

Relevant issues include:

Restrictions or adjustments affecting certain securities transactions.

Disruption of securities-market infrastructure.

Changes to issuer-disclosure arrangements.

Business interruptions.

Difficulty accessing foreign investment.

Financial and operational uncertainty.

The NSSMC has adopted special disclosure arrangements during martial law, including measures addressing historical reporting periods.

Its Resolution No. 09/21/4587/K03 of 10 June 2026 is also relevant to the regulation of public offerings and issuer disclosure during martial law.

Biotechnology companies must therefore check the current regulatory requirements rather than relying exclusively on pre-war compliance procedures.

nssmc.gov.ua+1

 

13. Major legal challenges

Legal challengePotential consequence
Misleading scientific disclosuresInvestor claims and regulatory action
Unlawful share issuanceDisputes over capital and ownership
Patent ownership conflictsReduced company valuation
Clinical-trial failureInvestment losses and litigation
Inadequate corporate governanceShareholder disputes
Securities fraudCivil, regulatory or criminal consequences
Foreign investment restrictionsTransaction delays or restrictions
Inaccurate financial reportingRegulatory and investor liability
Sanctions violationsTransaction restrictions and penalties

14. Recommendations for improving biotechnology securities governance in Ukraine

Ukraine could strengthen biotechnology-sector securities governance through the following measures:

1. Scientific disclosure standards: Develop clearer disclosure expectations for biotechnology companies, particularly for clinical-trial progress and experimental products.

2. Independent scientific verification: Encourage independent assessment of material scientific claims used in investment prospectuses.

3. Intellectual-property transparency: Require clear disclosure of patent ownership, licences and material patent disputes.

4. Investor protection: Strengthen monitoring of fraudulent biotechnology investment schemes.

5. Corporate governance: Encourage independent board oversight and transparent financial reporting.

6. Cross-border harmonisation: Continue aligning capital-market legislation with relevant European Union standards.

7. Research-financing transparency: Improve reporting on public grants, private investment and the commercialisation of publicly funded research.

8. Digital securities supervision: Improve the regulatory capacity to identify suspicious transactions and misleading investment disclosures.

15. Conclusion

Biotechnology Securities Law in Ukraine operates at the intersection of capital-market regulation, corporate governance, pharmaceutical regulation, intellectual-property protection and investor rights.

The principal legislation includes the Law on Capital Markets and Organised Commodity Markets, the Law on Joint-Stock Companies, the Law on the Depositary System and the Law on State Regulation of the Securities Market.

The National Securities and Stock Market Commission plays the central role in regulating securities issuance, disclosure and capital-market participants.

The Ukrainian Supreme Court's decisions concerning securities ownership, pharmaceutical share acquisitions and share-issue registration provide important judicial principles for biotechnology-sector investment disputes.

However, Ukraine still faces challenges concerning scientific disclosure, biotechnology valuation, intellectual-property ownership, foreign investment and investor protection.

The fundamental legal principle is that scientific innovation does not exempt biotechnology companies from ordinary securities-law obligations. Their securities offerings must be transparent, properly documented and compliant with Ukrainian law.

16. Important legal research sources

The following primary and judicial sources are useful for further academic research:

Ukrainian legislation – securities and corporate legislation.

Law No. 2465-IX – On Joint-Stock Companies.

NSSMC – Securities issuance and regulatory guidance.

Supreme Court – Securities ownership and depositary-account evidence, 19 April 2023.

Supreme Court – Review of securities-circulation jurisprudence, 24 June 2022.

Darnitsa pharmaceutical share-ownership litigation, 29 October 2020.

Academic note: This is a general legal research explanation based on identified Ukrainian legislation and judicial materials. For litigation or an actual securities offering, the current Ukrainian-language statutory text and full judgments should be checked.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT